Protocol

RADBEV: A Phase I Trial of RAD001 (Everolimus) and AVASTIN (Bevacizumab) in Children with Recurrent Solid Tumors

Diseases

Solid Tumor : Refractory/relapsed solid tumor or brain tumor

Description

This is a phase I study to find out if Everolimus and Bevacizumab can be given together to children and young adults for a tumor that has either come back after treatment (relapsed) or did not respond to therapy (refractory), the largest doses of these drugs that can be given safely, and to learn what the side effects are. The combination of the two drugs is experimental.

Recently, Bevacizumab was tested in a phase I study in limited number of children to determine the highest safe dose and the side effects of this drug in children. This study showed that Bevacizumab was very well tolerated in children and had very few side effects when given at the highest dose planned in the study.


Objectives


Eligibility criteria, among others, include:

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


Contact

Victor Santana, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only: protocolinfo@stjude.org

For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.